Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Eitaki, Masato ^a   Yamamori, Tohru ^a   Meike, Shunsuke ^a   Yasui, Hironobu ^a   Inanami, Osamu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CISPLATIN; ETOPOSIDE; F ACTIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR H1; MYOSIN LIGHT CHAIN; PACLITAXEL; PROTEIN KINASE; RHOA ASSOCIATED PROTEIN KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER INVASION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

ACTINS; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CISPLATIN; CYTOSKELETON; ETOPOSIDE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MYOSIN LIGHT CHAINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PACLITAXEL; PHOSPHORYLATION; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; STOMACH NEOPLASMS; VINCRISTINE;

EID: 84867294552     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-469     Document Type: Article

References (57)

1. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003, 17(Suppl 1):S27-S36.
2. Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis 2006, 26:99-114.
3. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007, 117(5):1305-1313. 10.1172/JCI30740, 1838926, 17415413.
4. Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, Lassau N, Bourhis J, Deutsch E. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005, 4(11):1717-1728. 10.1158/1535-7163.MCT-05-0179, 16275993.
5. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, Mukherjee N, Song Q, Robe P, Chakravarti A. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006, 76(3):227-237. 10.1007/s11060-005-6499-4, 16200346.
6. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5(4):e10365. 10.1371/journal.pone.0010365, 2860989, 20442777.
7. Mareel MM, De Brabander MJ. Effect of microtubule inhibitors on malignant invasion in vitro. J Natl Cancer Inst 1978, 61(3):787-792.
8. Mareel MM, Storme GA, De Bruyne GK, Van Cauwenberge RM. Vinblastine, Vincristine and Vindesine: anti-invasive effect on MO4 mouse fibrosarcoma cells in vitro. Eur J Cancer Clin Oncol 1982, 18(2):199-210. 10.1016/0277-5379(82)90064-5, 7201395.
9. Tonn JC, Haugland HK, Saraste J, Roosen K, Laerum OD. Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines. J Neurosurg 1995, 82(6):1035-1043. 10.3171/jns.1995.82.6.1035, 7539063.
10. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992, 52(13):3776-3781.
11. Westerlund A, Hujanen E, Höyhtyä M, Puistola U, Turpeenniemi-Hujanen T. Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis 1997, 15(3):318-328. 10.1023/A:1018481617275, 9174131.
12. Mashimo T, Bandyopadhyay S, Goodarzi G, Watabe M, Pai SK, Gross SC, Watabe K. Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Biochem Biophys Res Commun 2000, 274(2):370-376. 10.1006/bbrc.2000.3139, 10913345.
13. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11(4):239-253. 10.1038/nrc3007, 21430696.
14. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(Suppl 2):ii93-ii96.
15. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 1992, 10(8):1278-1283.
16. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241:27-39. edn. United States, 1356843, 15621988.
17. Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007, 7(10):737-749. 10.1038/nrc2229, 17891189.
18. Pinner S, Sahai E. Imaging amoeboid cancer cell motility in vivo. J Microsc 2008, 231(3):441-445. 10.1111/j.1365-2818.2008.02056.x, 18754999.
19. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003, 5(8):711-719. 10.1038/ncb1019, 12844144.
20. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev 2005, 15(1):87-96. 10.1016/j.gde.2004.12.002, 15661538.
21. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002, 52(4):255-264. 10.1046/j.1440-1827.2002.01343.x, 12031080.
22. Pankova K, Rosel D, Novotny M, Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci 2010, 67(1):63-71. 10.1007/s00018-009-0132-1, 2801846, 19707854.
23. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003, 160(2):267-277. 10.1083/jcb.200209006, 2172637, 12527751.
24. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006, 16(15):1515-1523. 10.1016/j.cub.2006.05.065, 16890527.
25. Charras G, Paluch E. Blebs lead the way: how to migrate without lamellipodia. Nat Rev Mol Cell Biol 2008, 9(9):730-736. 10.1038/nrm2453, 18628785.
26. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008, 181(6):879-884. 10.1083/jcb.200802081, 2426937, 18541702.
27. Paluch E, Sykes C, Prost J, Bornens M. Dynamic modes of the cortical actomyosin gel during cell locomotion and division. Trends Cell Biol 2006, 16(1):5-10. 10.1016/j.tcb.2005.11.003, 16325405.
28. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001, 114(Pt 15):2713-2722.
29. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269. 10.1146/annurev.cellbio.21.020604.150721, 16212495.
30. Yamazaki D, Kurisu S, Takenawa T. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 2009, 28(13):1570-1583. 10.1038/onc.2009.2, 19234490.
31. Rösel D, Brábek J, Tolde O, Mierke CT, Zitterbart DP, Raupach C, Bicanová K, Kollmannsberger P, Panková D, Vesely P, et al. Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res 2008, 6(9):1410-1420. 10.1158/1541-7786.MCR-07-2174, 18819929.
32. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007, 178(1):23-30. 10.1083/jcb.200701120, 2064414, 17606864.
33. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996, 271(34):20246-20249. 10.1074/jbc.271.34.20246, 8702756.
34. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4(6):446-456. 10.1038/nrm1128, 12778124.
35. Kolodney MS, Elson EL. Contraction due to microtubule disruption is associated with increased phosphorylation of myosin regulatory light chain. Proc Natl Acad Sci USA 1995, 92(22):10252-10256. 10.1073/pnas.92.22.10252, 40774, 7479762.
36. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10(12):842-857. 10.1038/nrc2960, 3124093, 21102635.
37. Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 2002, 4(4):294-301. 10.1038/ncb773, 11912491.
38. Chang YC, Nalbant P, Birkenfeld J, Chang ZF, Bokoch GM. GEF-H1 couples nocodazole-induced microtubule disassembly to cell contractility via RhoA. Mol Biol Cell 2008, 19(5):2147-2153. 10.1091/mbc.E07-12-1269, 2366883, 18287519.
39. Birkenfeld J, Nalbant P, Yoon SH, Bokoch GM. Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis?. Trends Cell Biol 2008, 18(5):210-219. 10.1016/j.tcb.2008.02.006, 18394899.
40. Sethi VS, Jackson DV, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, Spurr CL. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 1981, 41(9 Pt 1):3551-3555.
41. Owellen RJ, Donigian DW. [3H]Vincristine. Preparation and preliminary pharmacology. J Med Chem 1972, 15(9):894-898. 10.1021/jm00279a005, 5051004.
42. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011, 30:55. 10.1186/1756-9966-30-55, 3120716, 21569481.
43. Warlters A, Morris DL, Cameron-Strange A, Lynch W. Effect of electrohydraulic and extracorporeal shock waves on gastrointestinal cancer cells and their response to cytotoxic agents. Gut 1992, 33(6):791-793. 10.1136/gut.33.6.791, 1379338, 1624162.
44. James SE, Burden H, Burgess R, Xie Y, Yang T, Massa SM, Longo FM, Lu Q. Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology 2008, 29(4):605-612. 10.1016/j.neuro.2008.04.008, 2615238, 18539332.
45. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004, 265(1):23-32. 10.1016/j.ydbio.2003.06.003, 14697350.
46. Palazzo AF, Cook TA, Alberts AS, Gundersen GG. mDia mediates Rho-regulated formation and orientation of stable microtubules. Nat Cell Biol 2001, 3(8):723-729. 10.1038/35087035, 11483957.
47. Yamana N, Arakawa Y, Nishino T, Kurokawa K, Tanji M, Itoh RE, Monypenny J, Ishizaki T, Bito H, Nozaki K, et al. The Rho-mDia1 pathway regulates cell polarity and focal adhesion turnover in migrating cells through mobilizing Apc and c-Src. Mol Cell Biol 2006, 26(18):6844-6858. 10.1128/MCB.00283-06, 1592856, 16943426.
48. Nalbant P, Chang YC, Birkenfeld J, Chang ZF, Bokoch GM. Guanine nucleotide exchange factor-H1 regulates cell migration via localized activation of RhoA at the leading edge. Mol Biol Cell 2009, 20(18):4070-4082. 10.1091/mbc.E09-01-0041, 2743625, 19625450.
49. O'Neill GM. The coordination between actin filaments and adhesion in mesenchymal migration. Cell Adh Migr 2009, 3(4):355-357. 10.4161/cam.3.4.9468, 2802746, 19684475.
50. Etienne-Manneville S. Actin and microtubules in cell motility: which one is in control?. Traffic 2004, 5(7):470-477. 10.1111/j.1600-0854.2004.00196.x, 15180824.
51. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer 2003, 89(6):1123-1129. 10.1038/sj.bjc.6601257, 2376936, 12966436.
52. Wu W, Yamaura T, Murakami K, Ogasawara M, Hayashi K, Murata J, Saiki I. Involvement of TNF-alpha in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress. Oncol Res 1999, 11(10):461-469.
53. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4(9):e6896. 10.1371/journal.pone.0006896, 2731927, 19727403.
54. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, Ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2010, 128(3):657-666.
55. Kakiashvili E, Speight P, Waheed F, Seth R, Lodyga M, Tanimura S, Kohno M, Rotstein OD, Kapus A, Szászi K. GEF-H1 mediates tumor necrosis factor-alpha-induced Rho activation and myosin phosphorylation: role in the regulation of tubular paracellular permeability. J Biol Chem 2009, 284(17):11454-11466. 2670151, 19261619.
56. Kakiashvili E, Dan Q, Vandermeer M, Zhang J, Waheed F, Pham M, Szaszi K. The epidermal growth factor receptor mediates tumor necrosis factor-{alpha}-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium. J Biol Chem 2011, 286(11):9268-9279. 10.1074/jbc.M110.179903, 3059019, 21212278.
57. Tsapara A, Luthert P, Greenwood J, Hill CS, Matter K, Balda MS. The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration. Mol Biol Cell 2010, 21(6):860-870. 10.1091/mbc.E09-07-0567, 2836967, 20089843.